Italia markets closed
FTSE MIB
33.746,66 -549,65 (-1,60%) Dow Jones
37.815,92 -570,17 (-1,49%) Nasdaq
15.657,82 -325,26 (-2,04%) Nikkei 225
38.274,05 -131,61 (-0,34%) Petrolio
80,76 -1,17 (-1,43%) Bitcoin EUR
54.016,39 -3.845,38 (-6,65%)
UCB SA (UCBJF)
Other OTC - Other OTC Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 11:27AM EDT
| Chiusura precedente | 133,68 |
| Aperto | 133,68 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 133,68 - 133,68 |
| Intervallo di 52 settimane | 69,70 - 133,68 |
| Volume | |
| Media Volume | 111 |
| Capitalizzazione | 25,369B |
| Beta (5 anni mensile) | 0,40 |
| Rapporto PE (ttm) | 71,11 |
| EPS (ttm) | 1,88 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | 1,46 (1,09%) |
| Data ex dividendo | 26 apr 2024 |
| Stima target 1A | N/D |
GlobeNewswireClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
SOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical leader, to partner on drug delivery platforms for UCB’s gene therapy portfolio. “We are extremely excited to partner with UCB, a global biopharmaceutical leader, with a focus on inno
© 2024 Yahoo. Tutti i diritti riservati.